CR-6283 ,Statistical Analysis Plan Version 2.0 Page 1of 32[COMPANY_012] Vision 
STATISTICAL ANALYSIS PLAN
Protocol CR-6283
Initial Evaluation of Investigational Lenses Manufactured on a New Production Line
Acuvue OasysÂ® with Tansitionsâ„¢ (senofilcon A with new UV-blocker)
Version:2.0
Date:14 November 2018
Compliance: The study described in this document was performed according to the principles of Good 
Clinical Practice (GCP).
Confidentiality Statement
The information in this document contains trade secrets and com mercial information that are privileged or 
confidential and may not be disclosed unless such disclosure is  required by [CONTACT_784]. 
In any event, persons to whom the information is disclosed must  be informed that the information is 
privileged or confidential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure will 
apply equally to all future information supplied to you that is indicated as privileged or confidential.7*45%
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 2of 32AUTHORIZED SIGNATURES
The signature [CONTACT_636483] s the approval of this document a nd the attachments.
Author
Name :
[CONTACT_1641]: Biostatistician IIDATE
Reviewers
Name : .
Title: Senior Manage r of BiostatisticsDATE
Approvers
Name: [CONTACT_636484], O.D., M.S., F.A.A.O. 
Title: Principal Research Optometrist DATE4FF&MFDUSPOJD4JHOBUVSFJO5FBNDFOUFS
4FF&MFDUSPOJD4JHOBUVSFJO5FBNDFOUFS
4FF&MFDUSPOJD4JHOBUVSFJO5FBNDFOUFS
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850463] Article Allocation and Masking........................ .............................................. 7
3.5. Time and Event Schedule .................................... ................................................ 8
4. STUDY ENDPOINTS.............................................. ................................................. 9
4.1. Primary Endpoints ................................................................................................ 94.2. Secondary Endpoints ......................................................................................... 104.3. Other Endpoints............................................ ...................................................... 10
5. STATISTICAL HYPOTHESES FOR STUDY OBJECTIVES.................. ............... 11
5.1. Primary Hypotheses ......................................... .................................................. 11
5.2. Secondary Hypotheses ....................................... ............................................... 12
5.3. Other Hypotheses........................................... .................................................... 12
6. ANALYSIS SETS ................................................ .................................................. 13
6.1. All Enrolled ............................................... .......................................................... 13
6.2. Intent-to-Treat (ITT)...................................... ...................................................... 13
6.3. Safety Population .......................................... ..................................................... 13
6.4. Per-Protocol (PP) .......................................... ..................................................... [ADDRESS_850464] INFORMATION......................................... ........................................... 20
10.1. Disposition Information ................................... .................................................... 20
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 4of 3210.2. Protocol Deviations....................................... ...................................................... 21
10.3. Demographics and Baseline Characteristics ................. ..................................... 21
10.4. Treatment Compliance and Extent of Exposure ............... .................................. 21
10.5. Prior and Concomitant Medications......................... ........................................... 21
10.6. Medical History........................................... ........................................................ 21
11. STATISTICAL ANALYSIS ........................................ ............................................ 21
11.1. Primary Analysis.......................................... ....................................................... 21
11.2. Secondary Analysis......................................... ................................................... 27
11.3. Other Analysis ............................................................... ....................................... 28
12. SAFETY EVALUATION ........................................... ............................................. 31
12.1. Adverse Events ............................................ ...................................................... 31
12.2. Physical Examination Findings............................. .............................................. 31
12.3. Other Safety Parameters................................... ................................................. 31
13. REFERENCES .................................................. .................................................... 32
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 6of 321. INTRODUCTION
This statistical analysis plan (SAP) describes the analyses and  data presentations for protocol CR-
[ADDRESS_850465] ion in bright lighting, Slit Lamp 
Findings (Grade 3 or higher) and Distance Monocular logMAR Visual Acuity. This study will also 
aim to show that the Fit Acceptance rate is at least 90% while w earing the Test lens. The secondary 
objective of this study is to demonstrate non-inferiority of the  Test lens compare to the Control 
lens with respect to CLUE Overall quality of Vision and Handlin g and overall quality of vision 
outdoors.
This study also aims to explore the performance of Indoor, Outd oor and Driving performance 
using individual questionnaire items. 
3. STUDY DESIGN
3.1. Overview
This study is a randomized, 4-visit, partially subject-masked, 2x3 bilateral crossover, dispensing 
trial.  Approximately [ADDRESS_850466] 105 subjects 
complete.
The study begins with an initial visit (Visit 1). If a subject is found to meet all eligibility criteria, 
they will be randomized to one of two lens wear sequences (Test /Control/Control or 
Control/Test/Test). If the subject is dispensed their first study lenses at the initial visit then [ADDRESS_850467] follow-up visit will occur at approrimxatel y 2-weeks after intial dispensing 
(Visit 2). At visit 2, subjects will be dispensed their next lens as specified per the randomization.Subjects â€™follow-up for their second lens will occur approximately 2-week s after visit 2 (Visit 3). 
Subjects will be dispensed their last study lens (per the randomization) at visit 3 and will return 
for their final follow-up visit (visit 4) approximately 2-week after visit 3.  Unscheduled follow-up 
visits may occur during the study. Subjects will be advised to wear the study lenses at least five 
(5) days per week for at least six (6) hours per day for a peri od of two-weeks each. 
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850468] Articles
Table 1: Test Article Labels 
Test Article Label 
ACUVUE OASYSÂ®with Transitionsâ„¢ Test
ACUVUE OASYSÂ®Control
All Test Articles Total
3.3. Targeted Study Population and Sample Size
Approximately [ADDRESS_850469] lenses.  All subjects will be 
the age of 18 and <[ADDRESS_850470]/Control/Control or Control/Test/Test. Each lens will be wo rn for approximately 2 weeks in a 
bilateral fashion as DW totaling in a study duration of approximate ly 42 days (6 weeks) per subject.  
Table 2: Planned Enrollment St rategy by [CONTACT_636466] [ADDRESS_850471] Article Allocation and Masking
A computer-generated randomization scheme will be used to random ly assign subjects, in blocks 
of 2, to one of the two possible lens wear sequences (TEST/CONTR OL/CONTROL or 
CONTROL/TEST/TEST). The random scheme will be generated using t he PROC PLAN 
procedure from SAS Software Version 9.4 or higher (SAS Institute , Cary, NC).
The study site must follow the randomization scheme provided an d complete enrollment according 
to the randomization list and not pre-select or assign subjects . The randomized assignment of 
subjects will be performed at the first visit prior to the first fitting. The following must have 
occurred prior to randomization:
xInformed consent has been obtained
xSubject meets all the inclusion / exclusion criteria
xSubject history and baseline information has been collected.
Complete masking is impossible due to the functioning nature of  the Test lens.However, both the 
Test and Control were overlabeled in order to reduce bias as mu ch as possible since the Control 
lens may be the subjectâ€™s habi tual lens by [CONTACT_3364].  Therefore, the study is partially-subject  masked 
(Control lens only).
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 8of 323.5. Time and Event Schedule
Table 3: Time and Events Schedule 
Procedure BaselineTrial Fit & 
DispenseFollow -up Unscheduled Exit
Visit 1 1, 2, 3 2, 3, 4 PRN 4
Visit Window - - 13-15 Days - -
Estimated Visit Duration -V1: 2 
hoursV2, 3: 1 hour
V4: 1.[ADDRESS_850472]â€™s own contact [CONTACT_636467]3 -- - -
Habitual lens care [ADDRESS_850473] sensitivity (site 1036) - - 3 - -
Lens fitting assessment - 3 3 * -
Lens dispensing information 
and criteria- 3 -- -
Patient instructions - 3 - - -
Lens information - - 3 3 -
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 9of 32Procedure BaselineTrial Fit & 
DispenseFollow -up Unscheduled Exit
Visit 1 1, 2, 3 2, 3, 4 PRN 4
Visit Window - - 13-15 Days - -
Estimated Visit Duration -V1: 2 
hoursV2, 3: 1 hour
V4: 1.5 
hours- -
Compliance - - 3 3 -
Wearing times - - 3 3 -
CLUE Follow-Up
Questionnaire- - 3 * -
GSI Product Performance 
Questionnaire- - 3 * -
Symptoms - 3 3 3 -
Lens preference - - V3 - -
Surface characteristics - - 3 * -
Chief complaint, diagnosis, 
treatment- -- 3 -
* if wearing study contact [CONTACT_13276]
4. STUDY ENDPOINTS
4.1. Primary Endpoints
Primary Efficacy Endpoints:
CLUE Overall Comfort
Overall comfort scores will be assessed usin g the Contact [CONTACT_169754] (CLUEâ„¢)[ADDRESS_850474] lenses (comfort, vision, 
handling, and packaging) in a contact-lens wearing population i n the US, ages 18-65. Derived 
CLUE scores, using Item Response Theory (IRT), follow a normal d istribution with a population 
average score of 60 (SD 20), where higher scores indicate a mor e favorable/positive response. A
5 point increase in an average CLUE score translates into 10% s hift in the distribution of scores 
for a population of soft contact [CONTACT_19554]1.  The handling scores will be generated using the 
flexMIRT software version 3 or higher (Chapel Hill, NC).
Distance Monocular Contact [CONTACT_636468] (logMAR) is assessed for each subject eye at 
the two-week follow-up evaluation using EDTRS charts under two lighting conditions, (1) Bright 
illumination low contrast and (2) Dim Illumination High Contrast.
Vision Satisfaction in Bright Lighting
Vision satisfaction in bright light ingwill be assessed using the individual item 
â€œI was satisfied with the quality of my vision in bright light ingâ€ from the CLUEâ„¢ questionnaire. 
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 10of 32This item uses the response scale, 1: Strongly Disagree, 2: Disa gree, 3: Neither Agree nor 
Disagree, 4: Agree and 5: Strongly Agree. 
Primary Safety Endpoints:
Slit Lamp Findings (Grade 3 or Higher)
Slit Lamp Findings will be assessed using the FDA Grading scale ranfing from 0 to 4, where Grade 
0 represents the absence of findings and 1 to 4 representing su ccessively worse findings (i.e. Grade 
1=trace, Grade 2= mile, Grade 3=moderate and Grade 4= severe). The assessment will include 
conjunctival injection, corneal e dema, corneal neovasluralizati on, corneal staining, tarsal 
abnormalities or any other complication. SLF assessements will be conducted for each subject eye 
at all scheduled study visits(Fitting [Visit 1] and 2-Week Follow-up [Visit 2]). The percentage of eyes with Grade 3 or higher slit lamp findings will be analyzed ; eyes with multiple events will be 
counted only once.
Fit Acceptance Rate
Acceptable lens fit will be assessed for each subject eye at al l scheduled study visits (fitting [visit 
1] and follow-up [visit 2]).  Fit acceptance rate will be based  on the lens fit acceptance of eyes 
wearing the Test lens only.  Fit rates of the Control lens will  also be collected but are not a primary 
endpoint.
4.2. Secondary Endpoints
CLUE Overall Quality of Vision and Handling 
Overall Quality of vision and handling scores will be assessed u sing the Contact [CONTACT_506756] (CLUE)1questionnaire at the two-week follow-up.
Overall Quality of Vision Outdoors 
Overall quality of visio n outdoors will be assessed using the individual item 
â€œOverall quality of vision outdoors â€ from the market research questionnaire. This item uses the 
response scale, 0: Not Applicable, 1: Excellent, 2: Very Good, 3: Good, 4: Fair  and 5: Poor.
4.3. Other EndpointsLens Preferences
Lens preferences will be assessed by [CONTACT_636469]-week 
follow-up of the second wearing period (Visit 3). Subjects will be asked to choose for each 
preference item one of the following responses: Strongly Prefer  the first lens, Prefer the first lens, 
no preference, prefer the second lens, strongly prefer the seco nd lens. Lens preference questions 
consist of:
1.Overall lens preference 
2.Overall comfort 
3.Overall vision 
4.Overall reduction of glare 
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 11of 325.Overall preference indoors 
6.Overall preference outdoors 
7.Overall preference while driving during the day 
8.Overall preference while driving at night 
9.Overall preference while using computer screens & digital devices  
Driving Performance  
Driving performance will be assessed by [CONTACT_636470] (PRO) 
questions at the two-week follow-up evaluation. The individual items are as follows:
1.Reduction in glare while driving during the day 
2.Reduction in glare while driving during the night 
Indoor Performance 
Indoor performance will be assessed by [CONTACT_636471]-week follow-up 
evaluation. The individual items are as follows:
1.Reduction in glare from the comput er screen or digital devices 
2.Reduction in glare caused by [CONTACT_636472] 
3.Reduction in glare caused by [CONTACT_636473]-week follow-up 
evaluation. The individual items are as follows:
1.Ability to see comfortably in bright sunlight 
2.Reduction in glare in bright sunlight 
3.Reduction in squinting in bright sunlight 
4.Reduction in eye strain in bright sunlight 
All driving, indoor and outdoor (PRO) items above will be asses sed using the same excellence 
scale of; 0: Not Applicable, 1: Excellent, 2: Very Good, 3: Goo d, 4: Fair and 5: Poor. 
Contrast sensitivity will also be  evaluated during this study. 
5. STATISTICAL HYPOTHESES FOR STUDY OBJECTIVES
5.1. Primary Hypotheses
All primary hypotheses must be met in order to satisfy the prim ary objective of this study. 
1. The Test lens will be non-inferior to the Control lens with r espect to Distance Monocular 
logMAR Visual Acuity at the two-week follow-up evaluation under  both lighting 
conditions (Bright illumination low contrast and dim illuminati on high contrast). A non-
inferiority margin of 0.05 logMAR will be used.
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850475] to the percentage of 
eyes with Grade 3 or higher Slit Lamp Findings (Biomicroscopy) across all follow-up
visits (scheduled and unscheduled).  A non-inferiority odds rat io margin of 2 will be 
used.
3. The proportion of eyes with acceptable fit will be greater th an 90% across all visits 
(scheduled and unscheduled) for all subjects wearing the Test l ens.  
4. The Test lens will be non-inferior to the Control lens with respect to CLUE Overall 
Comfort at the two-week follo w-up evaluation.  A non-inferiorit y margin of -[ADDRESS_850476] lens will be superior to the Control lens in all 9 of the following lens preference 
items at the two-week follo w-up evaluation of the second wearin g period. 
a) Overall lens preference
b) Overall comfortc) Overall visiond) Overall reduction of glaree) Overall preference indoors
f) Overall preference outdoors
g) Overall preference while driving during the dayh) Overall preference while driving at nighti) Overall preference while using computer screens & digital dev ices
2. The Test lens will be superior to the Control lens in at leas t 2 of the following 4 indoor 
performance measures at the two-week follow-up evaluation.  
a) Reduction in squinting while using computer screens or digita l devices
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 13of 32b) Reduction in glare from the com puter screen or digital device s
c) Reduction in glare caused by [CONTACT_636472]
d) Reduction in glare caused by [CONTACT_636474]
3. The Test lens will be non-inferior to the Control lens with r espect to both of the following 
driving performance metrics at the two-week follow-up evaluatio n.  A cumulative odds 
ratio margin of 0.67 will be used. 
a) Reduction in glare while driving during the day
b) Reduction in glare while driving during the night
4. The Test lens will be superior to the Control lens in at leas t 2 of the following 4 outdoor 
performance measures at the two-week follow-up evaluation.  
a) Ability to see comfortably in bright sunlightb) Reduction in glare in bright sunlight
c) Reduction in squinting in bright sunlight
d) Reduction in eye strain in bright sunlight
5. At the 2-week follow-up evaluation, the difference in the are a under the contrast sensitivity 
function curve (measured by [CONTACT_636475] (qCSF) method) 
between the Test lens and the Control lens is more than -0.3 lo g unit.
6. ANALYSIS SETS
6.1. All Enrolled
The All Enrolled population will include all participants who s ign an informed consent.
6.2. Intent-to-Treat (ITT)Intent-to-treat will include all the subjects who were randomiz ed to study treatment. Subject will 
be analyzed as per randomi zed treatment (Planned Arm).
6.3. Safety PopulationThis analysis population will include all subjects who are rand omized and administered any test 
article. Safety analyses will be based on the safety population .
6.4. Per-Protocol (PP)Per Protocol Analysis set will be the primary analysis populati on. It will include all subjects who 
have successfully completed all v isits and did not substantiall y deviate from the protocol as 
determined by [CONTACT_636476]. Justification of 
excluding subjects with protocol deviations in the per-protocol  population set will be documented 
in a memo to file.
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 14of 327. DEFINITIONS AND DERIVED VARIABLES
7.1. Age
Age will be calculated using the Date of Birth (DOB) and the da te of the consenting the subject
and presented as age at las t birthday as an integer. 
Age = Integer part of [(Date of Baseline visit â€“Date of Birth) / 365.25]
7.2. Iris ColorIris color will categorized into either dark or light based on t he subjects hue and lightness of their 
iris using Johnson & Jonsons Iris Color Scale. If hue is brown or lightness is dark then the subject  
will be classified as having a dark iris, if hue is light then the subject will be classified as having a 
light iris. If lightness is medium and hue is green, blue or gr ey then the suject will be classified as 
having a light iris; otherwise subjects will be classified as h aving a dark iris.    
7.3. Visit WindowsTable 4: Visit Window information
Scheduled Visit 
NumberTime Interval
(label on output)Time Interval
(Day)aTarget Time 
Point
[ADDRESS_850477] treatment day is Day 1.
8. GENERAL STATISTICAL CONSIDERATIONS
8.1. Statistical Software
All data summaries and statistical analyses will be performed u sing the SAS software Version 9.4 
or higher (SAS Institute, Cary, NC)2.
8.2. Summary Statistics
Throughout the analysis of data, the results for each subject/e ye will be used when available for 
summarization and statistical analysis.  Unscheduled visits wil l be summarized separately and will 
be excluded from the statistical analysis.
Summary tables (descriptive statistics and/or frequency tables)  will be provided for all baseline
variables, efficacy variables and safety variables, as appropriate, by [CONTACT_636477] 
(fitting and follow-up).  Continuous variables will be summariz ed with descriptive statistics (n, 
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850478] deviation [SD], median, minimum and maximum). Fr equency count and 
percentage of subjects or eyes within each category will be pro vided for categorical data.
8.3. Reporting Numerical Values
Means, medians and confidence/credible intervals will be report ed to one decimal place greater 
than the original data. The standard deviation will be reported to two decimal places greater than 
the original data. Minimum and maximum will use the same number  of decimal places as the 
original data. P-values greater or equal than 0.0001 will be reported to 4 decimal places; p-values 
less than 0.0001 will be reported as â€œ<0.0001â€. All pe rcentages will be reported to one decimal 
place.
8.4. Sample Size Justification
This study was designed and powered to show non-inferiority of the Test lens compared to the 
Control lens with respect to logMAR Visual Acuity, Slit Lamp Fi ndings (Grade 3 or higher), 
CLUE comfort, handling and overall quality of vision. It was as sumed there was no difference 
between the Test and Control lens with respect to visual acuity  and slit lamp findings. Based on 
data from [ADDRESS_850479] lens is significantly superior to 90%. Unless otherwise specified, the sample size was 
calculated to achieve a minimum statistical power of 80% and a type I error of 5%. 
A total of 5 historical studies were utilized in the sample size calculation. Table 5 displays the studies, their corresponding study design and the number of sub jects enrolled and completed per-
protocol.  
Table 5: Historical Studies Inc luded in Sample Size Calculation 
Study Study Design Endpoints Collected No.
EnrolledNo. Completed 
Per-Protocol
2X3 Crossover CLUE, SLF Lens Fit 135 132
2X3 CrossoverCLUE, Visual Acuity 
(logMAR), SLF, Lens Fit133 121
2X3 Crossover CLUE, SLF Lens Fit 92 78
Single-Arm SLF, Lens Fit 54 48
Single-Arm SLF, Lens Fit 56 41
Table 6: Descriptive Summary of CLUE Scores by [CONTACT_636478] 
â€“2-Week Follow -up Evaluation  
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 16of 32CLUE Domain 
[Mean(SD)1] Test Control
Comfort  66.46 (22.20) 61.19 (24.20)
Handling 69.61 (19.18) 66.79 (20.01)
Overall Quality of Vision 64.15 (18.83) 60.33 (22.29)
1SD = Standard Deviation
Table 7: Descriptive Summary of Visual Acuity (logMAR) - â€“2-Week Follow -up
Evaluation
Visual Acuity High 
Illumination High Contrast Test Control
[Mean(SD)1] -0.0928 (0.[ZIP_CODE]) -0.0726 (0.[ZIP_CODE]) 
1SD = Standard Deviation
Table 8: Descriptive Summary of Mechanical Lens Fitting Pooled Across all Historical Studies    
Any Unacceptable Lens Fit1
[n(%)]Test n (%) Control n (%)
Fitting Evaluation 0(0.0) 0 (0.0)  
2-Week Follow-up 1 (0.05) 0 (0.0) 
Â¹The percent of any unacceptab le fit is calculated using Total Unique eyes as a denominator 
Table 9: Descriptive Summary of Slit Lamp Findings Pooled Acros s all Historical Studies
SLF Grade [ADDRESS_850480] n (%) Control n (%)
Corneal Edema 0 (0.0) 0 (0.0) 
Conjunctival Injection 55 (8.09) 59 (21.85) 
Tarsal Abnormalities 51 (5.93) 24 (8.89) 
Corneal Neovascularization 0 (0.0)  0 (0.0) 
Corneal Staining 2 (0.29) 0 (0.0) 
Other Findings 0 (0.0)  0 (0.0) 
Total Eyes (N) 680 270
Any SLF Grade 2Â² 108 (15.8) 83 (33.74) 
Any SLF Grade 3+ 0 (0.0) 0 (0.0) 
Total Unique Eyes 680 270
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 17of 32%= nx100/N; SD=Standard Deviation 
Â¹All SLF reported for this study are combined for the purposes of summarizing
Â² The percent (%) of Any Grade 2 is calculated using the Total U nique Eyes as the denominator
Table 10: Descriptive Summary of Individual Items from â€“2-Week Follow -up
Questionnaire Item/ Response Test Control
Vision Satisfaction in Bright Light [n(%)] 
Strongly Agree 65 (35.9) 35 (19.2)
Agree 89 (49.2) 95 (52.2)
Neither Agree Nor Disagree 24 (9.92) 17 ( 9.3)
Disagree 13 ( 7.2) 29 (15.9)
Strongly Disagree 0 (0.0) 6 ( 3.3)
Overall Quality of Vision Indoors [n (%)]
Excellent 100 (55.2) 80 (44.0)
Very Good 55 (30.4) 62 (34.1)
Good 23 (12.7) 30 (16.5)
Fair 3 (1.7) 7 (3.9)
Poor 0 (0.0) 3 (1.65) 
CLUE Comfort 
Sample size calculation for CLUE comfort was carried out using an approximation of the power 
of an F-test derived from the non-centrality parameter calculat ed form the observed F statistic of 
a linear model3.
Model details:
CLUE comfort was analyzed using a linear mixed model. Lens type was included as the only fixed 
effect.  An unstructured (UN) covariance matrix was used to mod el the correlation between 
measurements on the same subject across study periods.  Below i s the variance-covariance matrix 
used in the CLUE Comfort model. 
à·àµ­ÍµÍ»Í¹Ç¤Í³Íº Í³Í¶Í´Ç¤Í¶Íº Í³Í¶Í¶Ç¤Í·Í·
Í³Í¶Í´Ç¤Í¶Íº Í¶Í³Í³Ç¤ÍºÍ» Í´Í³Í²Ç¤Í»Í²Í³Í¶Í¶Ç¤Í·Í· Í´Í³Í²Ç¤Í»Í² ÍµÍ¹Í²Ç¤ÍºÍµàµ±
à¯–à¯¢à¯ à¯™à¯¢à¯¥à¯§Total Unique Subjects 340 135
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 18of 32Visual Performance (logMAR)
Sample size calculation for visual performance (logMAR) was car ried out using an approximation 
of the power of an F-test derived from the non-centrality param eter calculated form the observed 
F statistic of a linear model3.
Model details:
visual performance was analyzed using a linear mixed model. Len s type was included as the only 
fixed effect.  A compound symmetric (CS) covariance matrix was used to model the correlation 
between measurements on the same subject across study periods.  Below is the variance-
covariance matrix used in the visual performance model. 
à·àµ­Í²Ç¤Í²Í²ÍµÍ·Í³Íº Í²Ç¤Í²Í²Í²ÍµÍ¹Í¶ Í²Ç¤Í²Í²Í²ÍµÍ¹Í¶
Í²Ç¤Í²Í²Í²ÍµÍ¹Í¶ Í²Ç¤Í²Í²ÍµÍ·Í³Íº Í²Ç¤Í²Í²Í²ÍµÍ¹Í¶Í²Ç¤Í²Í²Í²ÍµÍ¹Í¶ Í²Ç¤Í²Í²Í²ÍµÍ¹Í¶ Í²Ç¤Í²Í²ÍµÍ·Í³Íºàµ±
à¯©à¯œà¯¦à¯¨à¯”à¯Ÿà¯£à¯˜à¯¥à¯™à¯¢à¯¥à¯ à¯”à¯¡à¯–à¯˜
Acceptable Lens Fit 
Acceptable lens fit is a binary response as y=[ADDRESS_850481] ey e has an acceptable fit and y=[ADDRESS_850482] lens therefore, the common reference rate of 95% was s elected for the sample size 
calculation, since this is considered to be a more conservative reference proportion. Assuming a 
correlation 0.[ADDRESS_850483] a nd period (intra-eye correlation);
and assuming a correlation of 0.[ADDRESS_850484] across periods.
A total of 2000 replicating trials were simulated to estimate a  s a m p l e  s i z e  w i t h  a  m i n i m u m  
statistical power of 80%.
Slit Lamp Findings
There were no Grade [ADDRESS_850485] and period; and a correlation of 0.[ADDRESS_850486] across 
periods (intra-subject correlation) . A reference rate of no more than 5% was assumed (worse-case 
scenario) with a non-inferiority odds ratio margin of 2. A total of 2000 replicating trials were simulated, each replicated sample was analyzed using a generali zed estimating equation (GEE) 
model with a binary distribution and the logit as the link func tion. Each model included lens type 
as the only fixed, eye was included as a random effect. The Odd s ratio and corresponding 95% 
confidence interval was used est imate differences between the T est and Control lenses. The upper 
limit of each 95% confidence interval was compared to 2; if the  upper limit was below 2 then 
NI=1; otherwise NI=0. Statistical power was calculated at the a verage NI. A sample size of 50 was 
chosen to achieve a minimum statistical power of 80%.  
The non-inferiority odds ratio margin of 2 corresponds to no mo re than a 5% difference between 
the Test and Control lenses assuming the Control reference rate  does not exceed 5%. 
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850487] we re included in the model as fixed 
effects. A variance component (VC) covariance structure was use d to model the measurements 
betwe en subjects across study periods. 
The non-inferiority cumulative odds ratio margin of 0.67 corres ponds to no more than a 10% 
difference between the Test and Control lenses assuming there i s no difference between study 
lenses. 
Table 11: Sample Size Estimates and Power Calculations for Primary Endpoints
EndpointNumber per 
Subjects to 
Complete Power
Distance Monocular Visual Acuity (logMAR) 4 80%
SLFs (Grade 3 or Higher) 50 80%
Acceptable lens Fit 65 80%
CLUE Comfort 30 87%
Vision Satisfaction in Bright Lighting 48 81%
Table12: Sample Size Estimate s and Power Calculations for Secon dary Endpoints
EndpointNumber per Subjects to 
Complete Power
CLUE Handling 30 81%
CLUE Overall Quality of Vision 30 82%
Overall Quality of Vision Indoors 95 81%
As indicated in Table [ADDRESS_850488] drop-out rate with 
be closely monitored, if an unexp ectedly high dropout rate is o bserved, then the targeted total 
enrollment number maybe be incr eased accordingly to ensure that  a minimum of 105 subjects 
complete the study. 
8.5. Statistical Significance Level
All planned analysis will be conducted with an overall type I error rate of 5%. There will be neither 
adjustment for multiple tests nor adjustment for multiplicity o f endpoints. Unless otherwise 
specified, all statistical t ests will be 2-sided.
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850489] dropout is grea ter than the 15%. The SAS/STAT 
procedures PROC MI and PROC MIANALYZE will be utilized with a parametric regression 
method used to make at least [ADDRESS_850490] INFORMATION
10.1. Disposition Information
Enrolled subjects will be allocated to one of the three mutuall y exclusive:
1. Completed: Subjects are considered to have completed the stud y if they (a) provided 
informed consent and/or assent; (b) they are eligible; (c) complet ed all three phases of 
testing; and (d) have not withdrawn/d iscontinued from the study.
2. Discontinued: Subjects are considered to have discontinued fr om the study if (i) test article 
was administered and (ii) discontinued from the study. Reasons for discontinuation 
include: (a) s ubjectâ€™s death during the study period (b) subject withdrawal of consent and/or 
assent (c) subject not compliant to protocol (d) subject lost to  follow-up (e) subject no 
longer meets eligibility criteria (e) subject develops significant or serious adverse events 
causing discontinuation of study lens wear (f) subject who have experience a Corneal 
Infiltrative Event (g) investigator â€™s clinical judgement regarding the subject safety reasons 
(that it is in the best interest of the subject to stop treatme nt) (h) subject missed any 
scheduled visit.
3. Assigned and Test Article Administered: Total number subjects  for which test articles were 
administered (Completed + Discontinued).
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 21of 324. Enrolled but Not Dispensed: Subjects are considered to be Enr olled Not Dispensed 
Subjects if they were (i) enrolled to the study (provided infor med consent and/or assent)
but failed to satisfy the eligibility criteria (inclusion/exclusion criteria) or (ii) if they are 
randomized but did not receive a test article. 
5. Total enrolled: Completed + Discontinued + Enrolled but Not D ispensed.
10.2. Protocol Deviations
Any protocol deviation that could impact the primary endpoints will result in the subject being 
excluded from the Per-Protocol analysis population. No analysis on protocol deviations will be 
performed. All reported protocol deviations will be listed.
10.3. Demographics and Baseline Characteristics
Demographic characteristics will be summarized by [CONTACT_340375]-Protocol,  safety, all enrolled and by [CONTACT_636479] v ariables, and numbers and 
percentages of subjects for categorical variables. Demographic i nformation will include age,
gender, race and ethnicity and iris category.
10.4. Treatment Compliance and Extent of Exposure 
Average daily wear time and average daily comfort wear time wil l be provided in the summary 
table. Non-compliance will be  reported in protocol deviation. 
10.5. Prior and Concomitant MedicationsPrior and concomitant medications will be documented during scr eening and updated during the 
study when applicable. A listing for both prior and concomitant  medications will be created for all 
enrolled subjects.
Disallowed medications for this study include: Oral retinoid isotretinoin (e.g. Accutane), oral 
tetracyclines, topi[INVESTIGATOR_171164], oral (e.g. Seldane, Chlor-T rimeton and Benadryl) and 
ophthalmic antihistamines, oral phenothiazines (e.g. Haldol, Mellaril, Thorazine, Elavil, Pamelor 
and Compazine), oral and ophthalmic Beta-Adrenergic blockers (e .g. Propranolol, Timolol and 
Practolol), systemic steroids a nd any prescribed or over the co unter (OTC) ocular medication. 
There are no disallowed concomitant therapi[INVESTIGATOR_411598].
10.6. Medical History
A listing of medical and surgical history will be created for a ll enrolled subjects.
11. STATISTICAL ANALYSIS
11.1. Primary Analysis
Primary efficacy analysis:
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 22of 32Visual Acuity
Distance monocular visual acuity (logMAR) will be tested under two conditions (bright 
illumination low contrast and dim illumination high contrast). Each condition will be analyzed 
separately using a Bayesian multivariate normal random-effects model to compare the Test and 
Control lenses. The regression model will include sequence of l ens wear, lens type and first-order 
carryover effect as fixed effects. Clinical site and subject ne sted within clinical site will be included 
as random effects. Other subject c haracteristics such as gender  and age will be included as fixed 
effects when appropriate. 
The Model:
Let İ•à¯œà¯à¯à¯Ÿà¯  = (İ•Í³à¯œà¯à¯à¯Ÿà¯  ,İ•Í´à¯œà¯à¯à¯Ÿà¯  ,İ•Íµà¯œà¯à¯à¯Ÿà¯  ) denote the visual acuity (logMAR) for the İ‰à¯§à¯›subject 
at the İˆà¯§à¯›site, assigned to the İ…à¯§à¯›lens for the İ†à¯§à¯›eye using the İ‡à¯§à¯›sequence at periods 1, 2, 3, 
respectively.  The likelihood for İ•à¯œà¯à¯à¯Ÿà¯  is constructed as follows: 
İ•à¯œà¯à¯à¯Ÿà¯  ~ N(ß¤à¯œà¯à¯à¯Ÿà¯ Ç¡Î£) 
Where ß¤à¯œà¯à¯à¯Ÿà¯  =áˆºÉŠÍ³à¯œà¯à¯à¯Ÿà¯ Ç¡ÉŠÍ´à¯œà¯à¯à¯Ÿà¯ Ç¡ÉŠÍµà¯œà¯à¯à¯Ÿà¯ áˆ»à¯and Î£ is a 3X3 variance-covariance matrix. Here, 
ÉŠÍ³à¯œà¯à¯à¯Ÿà¯  =ÉŠà¬´+  ß¨à¬µ+ßšà¬µİİŠİÜ®áˆ¾à¯œÇ¡à¯áˆ¿+ßšà¬¶İÜ¿İŠİİ‘İİÜµ à¯+                         ß›à¯Ÿ+ß™à¯
ÉŠÍ´à¯œà¯à¯à¯Ÿà¯  =ÉŠà¬´+  ß¨à¬¶+ßšà¬µİİŠİÜ®áˆ¾à¯œÇ¡à¯áˆ¿+ßšà¬¶İÜ¿İŠİİ‘İİÜµ à¯+ßšà¬·İ•İİÜ½Ü¥Í³ áˆ¾à¯œÇ¡à¯áˆ¿+ß›à¯Ÿ+  ß™à¯
ÉŠÍµà¯œà¯à¯à¯Ÿà¯  =ÉŠà¬´+  ß¨à¬·+ßšà¬µİİŠİÜ®áˆ¾à¯œÇ¡à¯áˆ¿+  ßšà¬¶İÜ¿İŠİİ‘İİÜµ à¯-ßšà¬·İ•İİÜ½Ü¥Í³ áˆ¾à¯œÇ¡à¯áˆ¿+ß›à¯Ÿ+ß™à¯
In this model ß¨à¬µÇ¡ß¨à¬¶Ç¡ß¨à¬·represent the effect of period with the constraint ß¨à¬µàµ…ß¨à¬¶àµ…ß¨à¬·= 0. Lens 
will be determined by [INVESTIGATOR_79714] k therefore lens i is denoted as  a function of k. We define İİŠİÜ®à¯œ=0 
for the Control lens and İİŠİÜ®à¯œ=[ADDRESS_850491] lens, sequence is defined as: Sequence=0 for th e 
order Control/Test/Test and Se quence=[ADDRESS_850492]/Control/C ontrol. The first-order carryover 
effect will be defined as carry=0 for the Control lens and carr y=[ADDRESS_850493] eye effects are independent and identi cally distributed (i.i.d) as ß™à¯Ì±
N(0, ßªà¯˜à¯¬à¯˜à¬¶) and the random subject effect is i.i.d. as ßœà¯ ~ N(0,ßªà¯¦à¯¨à¯•à¯à¯˜à¯–à¯§à¬¶) and the random site effect 
is i.i.d as ß›à¯Ÿ~ N(0, ßªà¯¦à¯œà¯§à¯˜à¬¶) for i=1,2 (lens),  j=1, 2  (eye), k=1, 2 (sequence), carry1=1, 2 (first-order 
carryover effect)  and  l=1â€¦| İ‰à¯Ÿ(subject/site)  and l=1,2, 3, 4, 5 and 6 (site).
For the Î² coefficients, independent non -informative priors N(0, 1000) will be used. For the 
variance of random effects ßªà¯˜à¯¬à¯˜à¬¶and ßªà¯¦à¯œà¯§à¯˜à¬¶independent non-informative conjugate priors inverse-
gamma(0.001, 0.001) will be used. For Î£, non -informative conjugate priors inverse-wishart(3,S) 
will be used where S is a 3X3 variance-covariance matrix of  İ•à¯œà¯à¯à¯Ÿà¯  . The metropolis sampler 
algorithm as implemented in the SAS/STAT MCMC 14.214procedure will be used to estimate the 
posterior distribution of the unknown parameters. Inferences wil l be made based on the 95% 
posterior credible interva ls for relevant parameters. 
Hypothesis Testing 
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 23of 32The null and alternative hypothesis for visual acuity (logMAR) to test for non-inferiority of the 
Test lens relative to the Control lens is as follows: 
Üªà¯¢Ç£ßšà¬µâ‰¥ 0.05
Üªà®ºÇ£ßšà¬µ< 0.05
Non-inferiority will be dec lared if the upper limit of the 95% credible interval of the difference 
between the Test and Control is below 0.05, i.e. P( ßšà¬µ< 0.05) â‰¥ 0.[ADDRESS_850494]  characteristics such as age, gender, 
race and iris category will be included when appropriate. 
The Model: 
Let İ•à¯œà¯à¯à¯Ÿ= (İ•Í³à¯œà¯à¯à¯Ÿ,İ•Í´à¯œà¯à¯à¯Ÿ,İ•Íµà¯œà¯à¯à¯Ÿ) denote the CLUE Comfort score for the İˆà¯§à¯›subject at the İ‡à¯§à¯›
site, assigned to the  İ…à¯§à¯›lens using the İ†à¯§à¯›sequence at periods 1, 2 and 3.  The likelihood for 
İ•à¯œà¯à¯à¯Ÿis constructed as follows: 
İ•à¯œà¯à¯à¯Ÿ~ N(ß¤à¯œà¯à¯à¯ŸÇ¡Î£) 
Where ß¤à¯œà¯à¯à¯Ÿ=áˆºÉŠÍ³à¯œà¯à¯à¯ŸÇ¡ÉŠÍ´à¯œà¯à¯à¯ŸÇ¡ÉŠÍµà¯œà¯à¯à¯Ÿáˆ»à¯and Î£ is a 3X3 variance-covariance matrix. Here, 
ÉŠÍ³à¯œà¯à¯à¯Ÿ=ÉŠà¬´+  ß¨à¬µ+ßšà¬µİİŠİÜ®áˆ¾à¯œÇ¡à¯áˆ¿+ßšà¬¶baseline +  ßšà¬·İÜ¿İŠİİ‘İİÜµ à¯ +ß›à¯
ÉŠÍ´à¯œà¯à¯à¯Ÿ=ÉŠà¬´+  ß¨à¬¶+ßšà¬µİİŠİÜ®áˆ¾à¯œÇ¡à¯áˆ¿+ßšà¬¶baseline +   ßšà¬·İÜ¿İŠİİ‘İİÜµ à¯+ßšà¬¸İ•İİÜ½Ü¥Í³ áˆ¾à¯œÇ¡à¯áˆ¿+ß›à¯
ÉŠÍµà¯œà¯à¯à¯Ÿ=ÉŠà¬´+  ß¨à¬·+ßšà¬µİİŠİÜ®áˆ¾à¯œÇ¡à¯áˆ¿+ßšà¬¶baseline +   ßšà¬·İÜ¿İŠİİ‘İİÜµ à¯-ßšà¬¸İ•İİÜ½Ü¥Í³ áˆ¾à¯œÇ¡à¯áˆ¿+ß›à¯
In this model ß¨à¬µÇ¡ß¨à¬¶Ç¡ß¨à¬·represent the effect of period with the constraint ß¨à¬µàµ…ß¨à¬¶àµ…ß¨à¬·= 0. Lens 
will be determined by [INVESTIGATOR_79714] j, therefore i is denoted as a function of j. We define Lens=0 for 
the Control lens and Â‡ÂÂ• àµŒ Í³ for the Test lens, sequence is defined as: Sequence=0 for the o rder 
Control/Test/Test and Sequence=[ADDRESS_850495]/Control/Control . The first-order carryover effect 
will be defined as carry=0 for the Control lens and carry=[ADDRESS_850496] to CL UE comfort; A positive ßšà¬µ
indicates the Test performed better than the Control. 
We assume random site effects are independent and identically d istributed (i.i.d) as ß›à¯~ N(0, 
ßªà¯¦à¯œà¯§à¯˜à¬¶)  for site for i=1,  2 (lens), j=1,  2 (sequence), k=1, 2, 3, 4, 5 and 6 (site).
For the Î² coefficients, independent non -informative priors N(0, 1000) will be used. For the 
variance of random effect of ßªà¯¦à¯œà¯§à¯˜à¬¶an independent non-informative conjugate prior, inverse-
gamma(0.001, 0.001) will be used. For Î£, non -informative conjugate priors inverse-wishart(3,S) 
will be used where S is a 3X3 variance-covariance matrix of  İ•à¯œà¯à¯à¯Ÿ. Starting values for the mean 
and variance of CLUE scores will be 60 and 400 (since standard deviation of CLUE is normalized 
to be 20), respectively. The Metropolis sampler algorithm as im plemented in the SAS/STAT 
MCMC 14.214procedure will be used to estimate the posterior distribution o f the unknown 
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 24of 32parameters. Inferences will be made based on the 95% posterior credible intervals for relevant 
parameters. 
Hypothesis Testing
The null and alternative hypothese s for CLUE comfort non-inferio rity of the Test lens relative to 
the Control lens are as follows: 
Üªà¯¢Ç£ßšà¬µâ‰¤ -5
Üªà®ºÇ£ßšà¬µ>- 5
Non-inferiority will be declared if the lower bound of the 2-si ded 95% credible interval of the 
difference between the Test lens and the Control lens is greate r than -5, i.e., P( ßšà¬µ>-5) â‰¥ 0.975. 
Vision Satisfaction in Bright Lighting
Vision satisfaction in bright lighting will be analyzed using a  Bayesian multinomial model for 
ordinal data.  The regression mode l will include sequence of le ns wear, lens type, period and first 
order carryover effect. Clinica l site and subject nested within  clinical site will be included as 
random effects. Other subject characteristics such as age, gender, race and iris category will be included when appropriate. 
The Model:
Let İ•
à¯œà¯à¯à¯Ÿà¯  = (İ•à¯œà¯à¯à¯Ÿà¯ à¬µ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¶ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬· ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¸ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¹ ) denote the rating for the İ‰à¯§à¯›subject, 
from the İˆà¯§à¯›site, assigned to the İ…à¯§à¯›study lens in the İ†à¯§à¯›period using the İ‡à¯§à¯›sequence. Possible 
values of İ•à¯œà¯à¯à¯Ÿà¯  are 1if the subject rating of vision satisfaction in bright lig hting are X and 0 
otherwise (x=1 for Strongly Agree and X=5 for Strongly Disagree, respectively).  The likelihood 
is constructed as follows: 
İ•à¯œà¯à¯à¯Ÿà¯  ~ Multinomial ( Ü²à¯œà¯à¯à¯Ÿà¯ à¬µ ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬¶ ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬· ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬¸ ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬¹ )
Ü²à¯œà¯à¯à¯Ÿà¯ à¬µàµŒß›à¯œà¯à¯à¯Ÿà¯ à¬µ
Ü²à¯œà¯à¯à¯Ÿà¯ à¯‘àµŒß›à¯œà¯à¯à¯Ÿà¯ à¯‘ -ß›à¯œà¯à¯à¯Ÿà¯ áˆºà¯‘à¬¿à¬µáˆ» 2 â‰¤ n â‰¤4
Ü²à¯œà¯à¯à¯Ÿà¯ à¬¹àµŒÍ³àµ† à· Ü² à¯œà¯à¯à¯Ÿà¯ à¯‘
à¯«à­€à¬µÇ¡Ç¤Ç¤à¬¸
Logit(ß›à¯œà¯à¯à¯Ÿà¯ à¯‘ )= ß à¯¡+ßšà¬µİİŠİÜ®à¯œáˆ¾à¯Ç¡à¯áˆ¿ +ßšà¬¶İ€İ‹İ…İİÜ² à¯à¬µ+ßšà¬·İ€İ‹İ…İİÜ² à¯à¬¶+ßšà¬¸İÜ¿İŠİİ‘İİÜµ à¯+ßšà¬¹İ•İİÜ½Ü¥à¯œáˆ¾à¯Ç¡à¯áˆ¿ +  
ß›à¯Ÿ+ßœà¯ áˆºà³—áˆ»
Where ß à¯¡is the intercept for levels n=1,2,3,4, Ü²à¯œà¯à¯à¯Ÿà¯ à¬µàµŒ Â”  áˆº ß› à¯œà¯à¯à¯Ÿà¯ à¬µàµŒÍ³ áˆ» with respect to the vision 
satisfaction in bright lighting item. We assume the random subj ect effects are independent 
identically distributed (i.i.d) as ßœà¯ áˆºà³—áˆ»~N(0, ßªà¯¦à¯¨à¯•à¯à¯˜à¯–à¯§à¬¶)for subject m nested within clinical site l and 
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 25of 32the random clinical site effects are i.i.d as ß›à¯Ÿ~N(0, ßªà¯¦à¯œà¯§à¯˜à¬¶) for i=1,2 (lens), j=1, 2, 3 (Period) k=1, 
2(Sequence) l=1, â€¦6 (Site) m=1, â€¦İŠà¯Ÿ(subject/site).
In this model, the lens I will be determined by [CONTACT_636480] j and sequence k, therefore i is denoted 
as a function of j and k. We define İİŠİÜ®à¯œ=0 for the Control lens and İİŠİÜ®à¯œ=[ADDRESS_850497] lens. 
The cumulative odds ratio for having higher rating can be writt en as OR= İà°‰à¬µ.
Independent vague N(0, 1000) prior s for the regression coeffici ents ßšà¯œi=1,â€¦5. For ß à¯¡, we are 
considering the following priors 
Ï€0(Î¸1) ~ N(0,100)
Ï€0(Î¸2| Î¸1) ~ N(0,100)I(Î¸ >Î¸1)
Ï€0(Î¸3| Î¸2) ~ N(0,100)I(Î¸ >Î¸2)
Ï€0(Î¸4| Î¸3) ~ N(0,100)I(Î¸ >Î¸3)
For the variance of random effects independent vague normal pri ors will also be used; 
ßªà¯‰à¬¶~inverse-gamma(0.001, 0.001) and ßªà¯¦à¬¶~inverse-gamma(0.001, 0.001). The Metropolis 
sample algorithim as implemented in the SAS/Stat MCMC Procedure  will be used to estimate 
the posterior distributions of the unknown parameters. Inferenc es will be made based on the 
posterior credible interval for  the relevant parameters. 
Hypothesis Testing
The null and alternative hypothe ses for superiority are as follows: 
Üªà¯¢Ü´Ü±â‰¤ 0.67
Üªà®ºÜ´Ü±> 0.[ADDRESS_850498] lens compared 
to the Control lens. Non-inferior ity will be declared if the lo wer bound of the 2-sided 95% 
credible confidence interval is above 0.67, i.e. P(OR= İà°‰à¬µ>0.67|y)=0.975.
Primary Safety Analysis: 
Lens Fit Acceptance
Lens fit acceptance will be analyzed using a Bayesian Logistic r egression random-effects model 
to estimate the proportion of subjectsâ€™ eyes wearin g the Test lens having acceptable lens fitting. 
The regression model will include period, sequence of lens wear and first order carryover effect as 
fixed effects. Site and subject will be included in the model as random effects. 
Let İ•à¯œà¯à¯à¯Ÿà¯  =[ADDRESS_850499] lens only and İ•à¯œà¯à¯à¯Ÿà¯ àµŒ0
otherwise for the İ‰à¯§à¯›subject, from the İˆà¯§à¯›site, for the İ…à¯§à¯›eye in the İ†à¯§à¯›period using the İ‡à¯§à¯›
sequence.
Â›[ZIP_CODE]Ì±Â‹ÂÂƒÂ”Â›áˆºÂ’ à­§à­¨à­©à­ªà­«áˆ»
Â’[ZIP_CODE]àµŒÂ‡ÂšÂ’áˆºÉŠà­§à­¨à­©à­ªà­«áˆ»
Í³àµ…Â‡ÂšÂ’ áˆºÉŠ à­§à­¨à­©à­ªà­«áˆ»
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 26of 32ÉŠà­§à­¨à­©à­ªà­« =È¾à¬´àµ…ßšà¬µİİŠİÜ®à¯œáˆ¾à¯Ç¡à¯áˆ¿àµ…È¾à¬·İ€İ‹İ…İİİŒ à¯à¬µàµ…È¾à¬¸İ€İ‹İ…İİİŒ à¯à¬¶àµ…È¾à¬¹Â•Â‡Â“Â—Â‡ÂÂ…Â‡ à­©àµ…È¾à¬ºİ•İİÜ½Ü¥Í³ à¯œáˆ¾à¯Ç¡à¯áˆ¿àµ…É€à­ªàµ…ßœà¯ áˆºà³—áˆ»+ 
ß™à¯áˆºà³˜áˆºà³—áˆ»áˆ» 
We assume the random subject eye effects are i.i.d as ß™à¯áˆºà³˜áˆºà³—áˆ»áˆ»Ì±áˆºÍ²Ç¡İİ•İßª Í´áˆ»for eye nested within 
subject within clinical site, the random effect for subject are i.i.d as ßœà¯ áˆºà³—áˆ»Ì±áˆºÍ²Ç¡İÜ¿İİ†Ü¾İ‘İßªÍ´áˆ»for subject 
nested within clinical site and the random clinical site effect s are i.i.d as É€à­«~N(0, ßªà¯¦à¯œà¯§à¯˜à¬¶)for i=1, 2 
(eye) , j=1, 2, 3 (period) k=1, 2(Sequence) l =1, â€¦ 6(Site) m=1, â€¦ İŠà¯Ÿ(subject/site).
For the È¾coefficients, independent non-informative priors áˆºÍ²Ç¡Í³Í²Í²Í²Í²áˆ» will be used. For the 
variance of random effects of ßªà¯˜à¯¬à¯˜à¬¶,Éà­±à­³à­ à­¨à­£à­¡à­²à¬¶andÉà­±à­§à­²à­£à¬¶, independent non-informative conjugate priors 
inverse-gamma (0.001, 0.001) will b e used. The Metropolis-Hasting s algorithm as implemented 
in the SAS/STAT 14.[ADDRESS_850500] to acceptable lens fit the null and alternative hy pothesis for superiority is as 
follows:
à¬´àµŒ Â’ àµ‘ Í²Ç¤Í»Í²
à¬µàµŒ Â’ àµ Í²Ç¤Í»Í²
Where, p represents the proportion of subject eyes that achieve  acceptable fit for the Test lens.
Where pis calculated as: 
Â’àµŒÂ‡ÂšÂ’áˆºÉŠáˆ»
Í³àµ…Â‡ÂšÂ’ áˆºÉŠáˆ»
And Î¼=È¾à¬´àµ…ßšà¬µàµ…à®’à°¯
à¬·àµ…à®’à°°
à¬·àµ…à®’à°±
à¬¶àµ…à®’à°²
à¬¶
Success for acceptable fit will  be declared if the lower bound of the 2-sided 95% credible 
interval of the proportion is greater than 0.90; i.e. áˆºÂ’ àµ Í²Ç¤Í»Í²áˆ»àµ’ Ç¤Í»Í¹Í· .
If the full planned model fails to converge, reduced versions m ay be considered.
Primary safety analysis:
Slit Lamp Findings
Grade [ADDRESS_850501] will be included in the model as random effects. 
Let İ•à¯œà¯à¯à¯Ÿà¯ à¯¡ =1 if a Grade 3 or higher SLF is observed and İ•à¯œà¯à¯à¯Ÿà¯ àµŒ0 otherwise for the İŠà¯§à¯›subject, 
from the İ‰à¯§à¯›site, assigned to the İ…à¯§à¯›study lens for the İ†à¯§à¯›eye in the İ‡à¯§à¯›period using the İˆà¯§à¯›
sequence.
Â›à­§à­¨à­©à­ªà­«à­¬Ì±Â‹ÂÂƒÂ”Â›áˆºÂ’ à­§à­¨à­©à­ªà­«à­¬áˆ»
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 27of 32Â’à­§à­¨à­©à­ªà­«à­¬àµŒÂ‡ÂšÂ’áˆºÉŠà­§à­¨à­©à­ªà­«à­¬áˆ»
Í³àµ…Â‡ÂšÂ’ áˆºÉŠ à­§à­¨à­©à­ªà­«à­¬áˆ»
ÉŠà­§à­¨à­©à­ªà­«à­¬ =È¾à¬´àµ…ßšÍ³İ†İ…İİŠİÜ®áˆ¾İ‡Ç¡İˆáˆ¿àµ…È¾à¬¶ÂƒÂ•Â‡ÂÂ‹ÂÂ‡	 à­ªàµ…È¾à¬·İ€İ‹İ…İİİŒ à¯à¬µàµ…È¾à¬¸İ€İ‹İ…İİİŒ à¯à¬¶àµ…È¾à¬¹Â•Â‡Â“Â—Â‡ÂÂ…Â‡ à­©àµ…
È¾à¬ºİ•İİÜ½Ü¥Í³İ…áˆ¾İ‡Ç¡İˆáˆ¿àµ…É€à­«àµ…İŠßœáˆºİ‰áˆ»àµ…ß™à¯áˆºà³™áˆºà³˜áˆ»áˆ»
We assume the random subject eye effects are i.i.d as ß™à¯áˆºà³™áˆºà³˜áˆ»áˆ»Ì±áˆºÍ²Ç¡İİ•İßªÈ€İÜ¿İİ†Ü¾İ‘İÈ€İİİ…İÍ´áˆ»for eye nested 
within subject within clinical site, the random effect for subj ect are i.i.d as ßœà¯¡áˆºà³˜áˆ»Ì±áˆºÍ²Ç¡ßªà¯¦à¯¨à¯•à¯à¯˜à¯–à¯§È€à¯¦à¯œà¯§à¯˜à¬¶áˆ»for 
subject nested within clinical site and the random clinical sit e effects are i.i.d as É€à­«~N(0, ßªà¯¦à¯œà¯§à¯˜à¬¶) for 
i=1,2 (lens), j=1, 2 (eye) , k=1, 2, 3 (period) l=1, 2(Sequence ) m=1, â€¦ 6 (Site) m=1, 
â€¦İŠà¯ (subject/site).
In this model, the lens I will be determined by [CONTACT_636480] k an d sequence l, therefore i is denoted 
as a function of j and k. We define İİŠİÜ®à¯œ=0 for the Control lens and İİŠİÜ®à¯œ=[ADDRESS_850502] lens.
The odds ratio for having a lower rate of SLFs can be written a s OR=İà°‰à¬µ.
For the È¾coefficients, independent non-informative priors áˆºÍ²Ç¡Í³Í²Í²Í²Í²áˆ» will be used. For the 
variance of random effects of ßªà¯˜à¯¬à¯˜à¬¶,Éà­±à­³à­ à­¨à­£à­¡à­²à¬¶andÉà­±à­§à­²à­£à¬¶, independent non-informative conjugate priors
inverse-gamma (0.001, 0.001) will b e used. The Metropolis-Hasting s algorithm as implemented 
in the SAS/STAT 14.2 PROC MCMC procedure will be used to estimate  posterior distributions 
of the unknown parameters. Inferences will be made based on the  posterior credible interval for 
the relevant parameters. 
Hypothesis Testing
The null and alternative hypothesis for Non-inferiority is as f ollows: 
Üªà¯¢Ç£OR â‰¥ 2
Üªà®ºÇ£< [ADDRESS_850503] lens having a lower rate of Grade 3 SLFs 
compared to the Control len s and is calculated as OR= İà°‰à¬µ. Non-inferiority will be established if 
the upper limit of the 2-sided 95% credible interval is below 2, i.e. P( Ü´Ü± <2 |y)=0.975. 
If the full planned model fails to converge, reduced versions m ay be considered. In the event that 
the number of Grade 3 or higher SLFs is too small Grade 2 or hi gher SLFs will be analyzed and 
tested as described above.
11.2. Secondary Analysis
Secondary efficacy analysis:
CLUE Overall Quality of Vision and Handling
CLUE Overall Quality of Vision a nd Handling will be analyzed an d test in the exact same 
manner as CLUE Overall Comfort. 
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 28of 32Overall Quality of Vision Indoors 
Overall quality of vision indoors will be analyzed and tested in the same manner as vision 
satisfaction in bright lighting. The only difference between the two models are the response set used to assess each ite m. For this model, 
Let İ•
à¯œà¯à¯à¯Ÿà¯  = (İ•à¯œà¯à¯à¯Ÿà¯ à¬µ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¶ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬· ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¸ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¹ ) denote the rating for the İ‰à¯§à¯›subject, 
from the İˆà¯§à¯›site, assigned to the İ…à¯§à¯›study lens in the İ†à¯§à¯›period using the İ‡à¯§à¯›sequence. Possible 
values of İ•à¯œà¯à¯à¯Ÿà¯  are 1if the subject rating of overall quality of vision indoors  are X and 0 otherwise 
(x=1 for Excellent and X=5 for Poor, respectively).  
Secondary safety analysis:
Not Applicable
11.3.OtherAnalysis
Other efficacy analysis:
Lens Preferences: 
Lens preference items listed below will be analyzed separately using Bayesian multinomial 
models for nominal data. 
1. Overall lens preference 2. Overall comfort 3. Overall vision 4. Overall reduction of glare 5. Overall preference indoors 6. Overall preference outdoors
7. Overall preference while driving during the day 
8. Overall preference while driving at night 9. Overall preference while using computer screens & digital dev ices 
The regression models will include lens wearing sequence, age a nd gender as fixed covariates 
when appropriate.  Investigational site will be included as ran dom effect if the variation across 
sites is not negligible. 
Let y
ijkl= (y ijk1,yijk2,yijk3,yijk4) denote subject lens preference for the ithsubject from the jthsite 
with regard to the kthpreference item. Possible values of y ijklare: y ijk1 = [ADDRESS_850504] lens, 0 otherwise; y ijk2 = [ADDRESS_850505] preferred the Control lens, 0 otherwise; y ijk3 = [ADDRESS_850506] and Control lenses, 0 ot herwise and y ijk4 = [ADDRESS_850507] nor Control  lenses, 0 otherwise. The likelihood of yijklis constructed as 
follow:
yijkl~ Multinomial (pi[INVESTIGATOR_636464]1,pi[INVESTIGATOR_636464]2,pi[INVESTIGATOR_636464]3,pi[INVESTIGATOR_636464]4)
pi[INVESTIGATOR_636465]= Î¸ijkl/ Æ©mÎ¸ijkl
log(Î¸ ijkl) = Î¼0kl+ Î²1kSequence ij+ Î²2kAge ij+ Î²3kFemale ij+ Î´j,
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 29of 32where Î¼ 0klare the intercepts with Î¼ 0k4set to 0, p ijkl= P(Y ijkl= 1) and Î³j~ N(0, Ïƒs2). We will use 
independent vague N(0,1000) priors for the regression coefficie nts Î¼0kl,Î²1k, Î²2kandÎ²3k, and 
IG(0.001, 0.001) for Ïƒs2.
Hypothesis Testing:
For each preference item, the null and alternative hypotheses for superiority are as follows: 
Ho: OR kâ‰¤ 1 Ha: OR k> 1; where OR krepresents the odds ratio of comparing the Test lens to the 
Control lens with regard to item k.  The odds ratio is calculat ed as:
OR k= p .k1(1- p. k2)/p. k2(1-p. k1),
where p. kl is the mean estimate p ijkl for k=1, ..., 5 and l = 1, â€¦, 4.
For each item k, the superiority will be declared if the lower b ound of the 2-sided 95% credible 
interval of OR kis greater than 1: Pr(OR k> 1|y) â‰¥ .975. 
Outdoor Glare Reduction 
Outdoor Glare reduction consists of 4 individual questionnaire items.
1. Ability to see comfortably in bright sunlight2. Reduction in glare caused by [CONTACT_636481] 3. Reduction of squinting in bright sunlight4. Reduction of eyestrain in bright sunlight 
All outdoor glare items are assessed using the same ordinal scale (1=Excellent â€¦5=Poor). Outdoor Glare reduction items will be analyzed separately using a Bayes ian multinomial model for ordinal 
data adjusting for baseline.  The regression model will include  sequence of lens wear, lens type, 
period and first order carryover effect. Clinical site and subject nested within clinical site will be included as random effects. Other subject characteristics such as age, gender, race and iris category 
will be included when appropriate. 
The Model:
Let İ•
à¯œà¯à¯à¯Ÿà¯  = (İ•à¯œà¯à¯à¯Ÿà¯ à¬µ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¶ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬· ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¸ ,İ•à¯œà¯à¯à¯Ÿà¯ à¬¹ ) denote the rating for the İ‰à¯§à¯›subject, 
from the İˆà¯§à¯›site, assigned to the İ…à¯§à¯›study lens in the İ†à¯§à¯›period using the İ‡à¯§à¯›sequence. Possible 
values of İ•à¯œà¯à¯à¯Ÿà¯  are 1if the subject rating of outdoor glare items are X and 0 o therwise (x=1 for 
Excellent and X=5 for Poor, respectively).  The likelihood is c onstructed as follows: 
İ•à¯œà¯à¯à¯Ÿà¯  ~ Multinomial ( Ü²à¯œà¯à¯à¯Ÿà¯ à¬µ ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬¶ ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬· ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬¸ ,Ü²à¯œà¯à¯à¯Ÿà¯ à¬¹ )
Ü²à¯œà¯à¯à¯Ÿà¯ à¬µàµŒß›à¯œà¯à¯à¯Ÿà¯ à¬µ
Ü²à¯œà¯à¯à¯Ÿà¯ à¯‘àµŒß›à¯œà¯à¯à¯Ÿà¯ à¯‘ -ß›à¯œà¯à¯à¯Ÿà¯ áˆºà¯‘à¬¿à¬µáˆ» 2 â‰¤ n â‰¤4
Ü²à¯œà¯à¯à¯Ÿà¯ à¬¹àµŒÍ³àµ† à· Ü² à¯œà¯à¯à¯Ÿà¯ à¯‘
à¯«à­€à¬µÇ¡Ç¤Ç¤à¬¸
[COMPANY_012] Vision Confidential
CR-6283 ,Statistical Analysis Plan Version 2.0 Page 30of 32Logit(ß›à¯œà¯à¯à¯Ÿà¯ à¯‘ )= ß à¯¡+ßšà¬µİİŠİÜ®à¯œáˆ¾à¯Ç¡à¯áˆ¿ +ßšà¬¶İ€İ‹İ…İİÜ² à¯à¬µ+ßšà¬·İ€İ‹İ…İİÜ² à¯à¬¶+ßšà¬¸İÜ¿İŠİİ‘İİÜµ à¯+ßšà¬¹İ•İİÜ½Ü¥à¯œáˆ¾à¯Ç¡à¯áˆ¿ +  
ß›à¯Ÿ+ßœà¯ áˆºà³—áˆ»
Where ß à¯¡is the intercept for levels n=1,2,3,4, Ü²à¯œà¯à¯à¯Ÿà¯ à¬µàµŒ Â”  áˆº ß› à¯œà¯à¯à¯Ÿà¯ à¬µàµŒÍ³ áˆ» with respect to outdoor 
glare preference. We assume the random subject effects are inde pendent identically distributed 
(i.i.d) as ßœ à¯ áˆºà³—áˆ»~N(0, ßªà¯¦à¯¨à¯•à¯à¯˜à¯–à¯§È€à¯¦à¯œà¯§à¯˜à¬¶)for subject m nested within clin ical site l and the random 
clinical site effects are i.i.d as ß›à¯Ÿ~N(0, ßªà¯¦à¯œà¯§à¯˜à¬¶) for i=1,2 (lens), j=1, 2, 3 (Pe riod) k=1, 2(Sequence) 
l=1, â€¦5 (Site) m=1, â€¦ İŠà¯Ÿ(subject/site).
In this model, the lens I will be determined by [CONTACT_636480] j an d sequence k, there fore i is denoted 
as a function of j and k. We define İİŠİÜ®à¯œ=0 for the Control lens and İİŠİÜ®à¯œ=[ADDRESS_850508] lens. 
The odds ratio for having higher rating can be written as OR= İà¬¿à°‰à¬µ.
Independent vague N(0, 1000) prior s for the regression coeffici ents ßšà¯œi=1,â€¦5. For ß à¯¡, we are 
considering the following priors 
Ï€0(Î¸1) ~ N(0,100)
Ï€0(Î¸2| Î¸1) ~ N(0,100)I( Î¸>Î¸1)
Ï€0(Î¸3| Î¸2) ~ N(0,100)I( Î¸>Î¸2)
Ï€0(Î¸4| Î¸3) ~ N(0,100)I( Î¸>Î¸3)
For the variance of random effects independent vague normal priors will also be used; ßªà¯‰à¬¶~inverse-
gamma(0.001, 0.001) and ßªà¯¦à¬¶~inverse-gamma(0.001, 0.001). The Metropolis sample algorithim 
as implemented in the SAS/Stat MCMC Procedure will be used to e stimate the posterior 
distributions of the unknown parameters. Inferences will be mad e based on the posterior credible 
interval for the relevant parameters. 
Hypothesis Testing
The null and alternative hypothe ses for superiority are as follows: 
Üªà¯¢Ü´Ü±â‰¤ 1
Üªà®ºÜ´Ü± >[ADDRESS_850509] lens compared 
to the Control lens where the OR is calculated as OR= İà¬¿à°‰à¬µ. Superiority will be declared if the 
lower bound of the 2-sided 95% credi ble confidence interval is above 1, i.e. 
P(OR=İà¬¿à°‰à¬µ>1|y)=0.975.
Indoor Glare Reduction
Indoor Glare reduction consists of 4 individual questionnaire i tems:
1. Reduction in squinting while using computer screens or digita l devices
2. Reduction in glare from the com puter screen or digital device s
3. Reduction in glare caused by [CONTACT_636472]
4. Reduction in glare caused by [CONTACT_636482] w indow
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850510]  same manner as the Outdoor 
Glare Reduction Items described above. 
Driving Measures
Driving measure consists of two individual questionnaire items:
1. Reduction in glare while driving during the day
2. Reduction in glare while driving during the night
Each item will be analyzed indivi dually in the exact same manner as the Outdoor Glare 
Reduction Items described above. How ever, the hypothesis test wi ll be as follows: 
Hypothesis Testing
The null and alternative hypothe ses for superiority are as follows: 
Üªà¯¢Ü´Ü±â‰¤ 0.67
Üªà®ºÜ´Ü± >0.[ADDRESS_850511] lens compared to the Control lens. Non-inferiority will be declared if the lower bound of the 2-sided 95% credible 
confidence interval is above 0.67, i.e. P(OR= İ
à¬¿à°‰à¬µ>0.67|y)=0.975. Superiority will be declared if 
the lower bound of the 2-sided 95% credible interval is above 1 , i.e. P(OR= İà¬¿à°‰à¬µ> 1|y)=0.975.
Superiority will only be tested i n the event that non-inferiori ty is established. 
12. SAFETY EVALUATION
12.1. Adverse Events
Listings of all reported ocular  and non-ocular AEs and SAEs will be reported.  
12.2. Physical Examination Findings
Slit lamp findings will be summar ized by [CONTACT_340379]. The slit la mp assessment will evaluate the 
following 
xCorneal Edema 
xCorneal Infiltrates 
xCorneal Neovascularization 
xCorneal Neovascularization Location 
xCorneal Staining 
xCorneal Staining Location 
xConjunctival Injection 
xTarsal Abnormalities 
xOther 
12.3. Other Safety ParametersCorneal Staining Area, Type and Depth as well as Conjunctival R edness (Bulbar and Limbal) will 
be descriptively summarized by [CONTACT_340379]. Expanded corneal staini ng will be assessed in the 
following locations:
[COMPANY_012] Vision Confidential
CR-[ADDRESS_850512] Lens User Experie nce: CLUE Scales. Optom 
Vis Sci. 2016; 93(8): 801-808.
2. SAS Institute Inc: SASÂ® 9.4 Statements: Reference, Third Editi on. Cary, NC: SAS 
Institute Inc; 2014.  
3. Stroup, WS. Generalized linear mixed models . 2012, Boca Raton: CRC Press.